Literature DB >> 27008304

Percutaneous Sacroplasty under Fluoroscopic Guidance Combined with Epidurogram for Sacral Insufficiency Fracture Resulting from Metastatic Tumor and Osteoporosis.

Sooyoung Cho1, Hahck Soo Park2, Dong Yeon Kim, Chi Hyo Kim1, Rack Kyung Chung1, Youn Jin Kim1.   

Abstract

Sacral insufficiency fracture resulting from a metastatic tumor or an osteoporotic fracture causes severe low back pain and radiating pain mass effect on neural foramen and chemical irritants. Percutaneous sacroplasty is one of the effective treatment modalities for sacral insufficiency fracture and its pain. Because of the structural complexity of the sacrum, obtaining an epidurogram of the S1 and S2 nerve roots before the start of the procedure can be helpful to avoid nerve injury. We present 2 successful cases of percutaneous sacroplasty performed under fluoroscopic guidance. A 65-year-old man with sacral metastasis from stomach cancer and a 52-year-old man with sacral insufficiency fracture were suffering from severe buttock pain and radiating pain. After epidurography of the S1 and S2 nerve roots with steroid and contrast dye, percutaneous sacroplasty with fluoroscopy on the S1 or S2 body and alae was performed on both patients. There was no cement leakage or any other major complications. Both patients experienced significant reduction in pain.

Entities:  

Mesh:

Year:  2016        PMID: 27008304

Source DB:  PubMed          Journal:  Pain Physician        ISSN: 1533-3159            Impact factor:   4.965


  2 in total

Review 1.  Sacral Insufficiency Fractures: a Review of Risk Factors, Clinical Presentation, and Management.

Authors:  Ivan Urits; Vwaire Orhurhu; Jessica Callan; Nishita V Maganty; Sara Pousti; Thomas Simopoulos; Cyrus Yazdi; Rachel J Kaye; Lauren K Eng; Alan D Kaye; Laxmaiah Manchikanti; Omar Viswanath
Journal:  Curr Pain Headache Rep       Date:  2020-02-17

2.  Fluoroscopy-Guided Percutaneous Sacroplasty for Painful Metastases at the Sacral Ala.

Authors:  Qing-Hua Tian; He-Fei Liu; Tao Wang; Chun-Gen Wu; Ying-Sheng Cheng
Journal:  J Pain Res       Date:  2020-01-16       Impact factor: 3.133

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.